CL2012000650A1 -
Compounds derived from substituted dihydrobenzocycloalkyloxymethyl oxazolopyrimidones, allosterocal modulators of metabortropic glutamate receptors (mglur); pharmaceutical composition comprising them; and use for the treatment and / or prevention of diseases associated with CNS, such as anxiety, migraine, pain, among others.
- Google Patents
Compounds derived from substituted dihydrobenzocycloalkyloxymethyl oxazolopyrimidones, allosterocal modulators of metabortropic glutamate receptors (mglur); pharmaceutical composition comprising them; and use for the treatment and / or prevention of diseases associated with CNS, such as anxiety, migraine, pain, among others.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SafiledCriticalSanofi Sa
Publication of CL2012000650A1publicationCriticalpatent/CL2012000650A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Compuestos derivados de oxazolopirimidinonas sustituidas, moduladores del receptor de glutamato (MGLUR); composición farmacéutica que los comprende; uso para el tratamiento de ansiedad, migraña, esquizofrenia, trastornos cognitivos, epilepsia y dolor.Compounds derived from substituted oxazolopyrimidinones, modulators of the glutamate receptor (MGLUR); pharmaceutical composition comprising them; use for the treatment of anxiety, migraine, schizophrenia, cognitive disorders, epilepsy and pain.
CL2012000650A2009-09-152012-03-14
Compounds derived from substituted dihydrobenzocycloalkyloxymethyl oxazolopyrimidones, allosterocal modulators of metabortropic glutamate receptors (mglur); pharmaceutical composition comprising them; and use for the treatment and / or prevention of diseases associated with CNS, such as anxiety, migraine, pain, among others.
CL2012000650A1
(en)
Compounds derived from substituted dihydrobenzocycloalkyloxymethyl oxazolopyrimidones, allosterocal modulators of metabortropic glutamate receptors (mglur); pharmaceutical composition comprising them; and use for the treatment and / or prevention of diseases associated with CNS, such as anxiety, migraine, pain, among others.
Compounds derived from substituted 6-amino-nicotinamides, as modulators of kcnq2 / 3; pharmaceutical composition that includes them, useful for the treatment and / or prophylaxis of disorders and / or selected diseases of pain, epilepsy, anxiety, cognitive diseases, among others.
Compounds derived from carboxamide; pharmaceutical composition that includes them, and their use as inhibitors of phosphodiesterase type 10a (pde10a) for the treatment of CNS disorders, schizophrenia, cognitive dysfunction related to schizophrenia, bipolar disorders, depression, cognitive dysfunction, cognitive disorders, behavioral disorders associated with Alzheimer's disease, obesity, huntington's disease and anxiety.
Use of compounds derived from benzamide to treat disorders of the central nervous system selected from depression, anxiety, psychotic disorders, neurological disorders, epilepsy, cardiovascular disorders, diabetes, dyslipidemias, among others; benzamide derived compounds; pharmaceutical composition; and use of the composition.
2-Oxo-1-pyrrolidinyl-imidazothiadiazole derived compounds; pharmaceutical composition comprising them; useful for the treatment of epilepsy, neurological disorders, among others.
Compounds derived from 1,3-disubstituted-4-phenyl-1h-pyridin-2-one, allosteric modulators of the glutamatergic receptor mglur2; Pharmaceutical composition and use of the compounds in the treatment of neurological and psychiatric conditions mediated by mglur2.
Agonist and antagonist compounds of the s1p5 receptor; and use of the compounds in the preparation of medicaments useful for the treatment of diseases mediated by the s1p refceptor, such as neurodedenerative diseases.
Compounds derived from 4- (4-aryl-o-phenyl) -1h-pyridin-2-one; 4- (4-aryl-s-phenyl) -1h-pyridin-2-one; 4- (4-aryl-so-phenyl) -1h-pyridin-2-one; 1,3-disubstituted 4- (4-aryl-so2-phenyl) -1h-pyridin-2-one and 4- (4-aryl-cf2-phenyl) -1h-pyridin-2-one; composition comprising them; and use for the treatment and / or prevention of CNS disorders involving the mglur2 receptor.
Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
Compounds derived from substituted pyrazolo-pyrimidines; pharmaceutical composition and combination that comprise them; and its use as inhibitors of pde9 for the treatment, relief and / or prevention of cognitive impairments related to perception, Alzheimer's, sleep disorders, bipolar disorder, diabetes mellitus.
Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
Compounds derived from amides, modulators of the taar1 receptor; obtaining process; pharmaceutical composition; and use in the treatment of diseases such as depression, anxiety, stress, among others.
Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others.